

### **REMARKS/ARGUMENTS**

In a March 16, 2009 response to the final Office action, Applicants amended the claims. Claims 5, 8-16 and 18 are currently pending. Claim 5 was amended to include the limitation of cancelled claim 6. Claim 18 was similarly amended.

In the Examiner's final Office action, the subject matter of claim 6 was rejected only under 35 U.S.C. §102(b) or 102(e) by Belew et al. This rejection was rebutted in Applicants' response of March 16, 2009, as it applies to the newly amended claim 5. However, in the advisory action, the Examiner states that the amendment would not overcome Belew et al. in view of Prior et al. (i.e., the rejection under 35 U.S.C. §103(a)). Applicants submit that this seems to be an error. Applicants respectfully seek clarification.

Applicants respectfully submit that as discussed in the response of March 16, 2009, claims 5, 8-16 and 18 are allowable.

Appl. No. 10/589,717  
Amendment dated May 15, 2009  
Reply to Office action of December 15, 2008

Early and favorable consideration is respectfully requested.

Respectfully submitted,

GE Healthcare Bio-Sciences Corp.

By: /Yonggang Ji/  
Yonggang Ji  
Reg. No.: 53,073  
Agent for Applicants

GE Healthcare Bio-Sciences Corp.  
800 Centennial Avenue  
P. O. Box 1327  
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875  
Fax: (732) 457-8463

I hereby certify that this correspondence is being uploaded to the United States Patent and Trademark Office using the Electronic Filing System on May 15, 2009.

Signature: /Melissa Leck/

Name: Melissa Leck